Cure8 research brief
The study suggests chronic gut inflammation can cause measurable brain inflammation and neuronal dysfunction in an IBD model, and that creatine supplementation prevented those changes — a potential neuromodulatory approach that could interest people with IBD who experience cognitive or mood symptoms.
Researchers studying the gut–brain axis, clinicians interested in neuropsychiatric comorbidities of IBD, and patients curious about nutraceutical approaches to inflammation-driven brain symptoms.
This paper used a rat model of ulcerative colitis (dextran sulfate sodium) to study hippocampal structure and electrophysiology. Male rats showed more severe colitis-associated hippocampal inflammation and neuronal damage than females.
Creatine given orally restored hippocampal creatine levels and prevented microglial activation, neuronal damage, and electrophysiological abnormalities that were caused by colitis in this model.
The study is preclinical (animal) and reports mechanistic and protective effects of creatine in that experimental context; it does not provide evidence that creatine will have the same effects in people with IBD. Decisions about supplements or treatments should be made with a clinician.
This is an animal (rat) experimental study using a chemical colitis model; results may not translate directly to humans. The article abstract reports structural and electrophysiological measures and sex differences, and describes creatine as protective in that model.
The study should be seen as preclinical evidence that may justify further research, not clinical proof of benefit in people with IBD.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study describes a new oral, colon‑targeted delivery system that improved outcomes in a mouse model of ulcerative colitis and shifted immune and microbiome markers—research that could inform future therapies focused...
The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
